National Policy for Rare Diseases (NPRD)
Core Classifications and Definitions
- The National Policy for Rare Diseases (NPRD) is the central statutory framework governing the screening, diagnosis, and financial aid for patients suffering from 63 formally notified rare diseases in India.
- Originally notified in 2021, it underwent critical operational and funding upgrades in 2025 to expedite access to high-cost orphan drugs and targeted therapies.
- Epidemiological Baseline: India lacks a prevalence-based definition due to absent epidemiological data. The MoHFW National Policy for Rare Diseases (NPRD) categorizes recognized conditions based on clinical manageability and treatment costs.
- Burden: Rare diseases affect an estimated 70 to 100 million individuals in India. Over 70% of the approximately 450 identified rare disorders are genetic and manifest primarily during childhood.
- Statutory Disease Categorization (NPRD 2021):
| Disease Category | Clinical Description | Pediatric Clinical Examples |
|---|---|---|
| Group 1 | Disorders amenable to one-time curative treatment (e.g., HSCT or organ transplantation). | Lysosomal Storage Disorders (LSDs) lacking ERT, Severe Combined Immunodeficiency (SCID), Osteopetrosis, Biliary Atresia. |
| Group 2 | Diseases requiring long-term/lifelong manageable treatment with relatively lower costs (dietary formulae or specific hormones). | Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Congenital Adrenal Hyperplasia. |
| Group 3 | Disorders requiring definitive, high-cost, lifelong targeted therapies (with optimal patient selection challenges). | Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), Pompe Disease, Gaucher Disease. |
Public Health Rationale and Objectives
- Diagnostic Odyssey Mitigation: Aimed to drastically reduce the 5 to 7-year diagnostic delay typical for rare genetic disorders through decentralized screening.
- Preventive Focus: Emphasizes primary, secondary, and tertiary prevention, specifically focusing on prenatal screening, high-risk genetic counseling, and universal newborn screening for select metabolic errors.
- Indigenous R&D: Mandates the creation of a conducive environment for domestic orphan drug manufacturing and pharmacogenomics.
Execution and Clinical Implementation
- Financial Entitlements (2025 Updates):
- The 2025 operational update explicitly provides a lifetime financial support cap of ₹50 lakh per patient under the Rashtriya Arogya Nidhi (RAN).
- Critically, this funding is now applicable across all three disease groups for the 63 formally notified rare diseases, shifting from the original 2021 restriction.
- Full exemption from Goods & Services Tax (GST) and Basic Customs Duty is granted for orphan drugs and Foods for Special Medical Purposes (FSMP) imported for personal use or via designated centers.
- Institutional Infrastructure:
- Centres of Excellence (CoEs): Expanded to over 15 premier government tertiary hospitals (e.g., AIIMS New Delhi, KEM Mumbai) equipped for definitive diagnosis and treatment delivery.
- Nidan Kendras: Established by the Department of Biotechnology under the UMMID project to provide regional genetic testing and prenatal counseling.
- Digital and Data Framework:
- NRROID: The ICMR hosts the National Registry for Rare and Other Inherited Disorders to track epidemiology and patient outcomes centrally.
- Digital Crowdfunding Portal: A government-hosted digital platform designed to pool voluntary individual, corporate, and CSR donations directly into CoE hospital accounts to supplement treatment costs.
- Pediatric Workflow (IAP Guidelines):
- Pediatricians are the designated first point of contact for clinical red flags (organomegaly, neuroregression).
- Must trigger Next-Generation Sequencing (NGS) panels and immediately refer confirmed/suspected cases to CoEs for funding registration.
- Integration with Rashtriya Bal Swasthya Karyakram (RBSK) mobile health teams and District Early Intervention Centers (DEICs) is mandated for early defect detection.
Critical Appraisal
| Domain | Policy Strengths & Opportunities | Severe Limitations & Implementation Gaps |
|---|---|---|
| Financial Access | The ₹50 lakh grant democratizes initial access to life-saving interventions across a wide demographic. | Cap Insufficiency: ₹50 lakh is grossly inadequate for lifelong Group 3 therapies (e.g., Zolgensma for SMA, ETI for Cystic Fibrosis), causing critical treatment interruptions. |
| Alternative Funding | Establishes a structured digital portal for CSR and philanthropic crowdfunding. | Crowdfunding Failure: The portal lacks recurring giving features; it has raised nominal sums (e.g., ~₹3.9 lakh) against a requirement exceeding ₹9,100 crore annually. |
| Diagnostic Equity | Duty exemptions and Nidan Kendras dramatically reduce transaction costs and out-of-pocket screening expenses. | Exclusion Constraints: Patients with unlisted, ultra-rare diseases are automatically ineligible for RAN funding, leaving them without a structured diagnostic or therapeutic pathway. |
| System Visibility | NRROID provides the first synchronized clinical database for tracking Indian specific phenotypes. | Transparency Deficits: Lack of real-time public data regarding CoE fund disbursal timelines and patient waitlists leads to fatal administrative delays. |
Synthesis and Future Horizons
- Judicial Intervention: Ongoing Supreme Court and Delhi High Court directives have pressured the Union government to establish a continuous, 'pooled' National Fund for Rare Diseases to guarantee multi-year treatment continuity beyond the ₹50 lakh cap.
- State-Level Innovations:
- Kerala: Utilizes centralized pooled procurement (KMSCL) for rare disease drugs to anchor price discovery and stabilize supply.
- Goa: Notified a Pricing Policy enabling confidential negotiated pricing to reduce effective acquisition costs.
- Rajasthan: Launched a state-backed portal (RajSambal) aiming toward premium-backed fund pooling.
- Future Scope: Urgent calls remain for the establishment of a dedicated Office for Rare Diseases and Orphan Products in India, mandatory integration of genetic testing into routine tertiary care, and utilizing the Production Linked Incentive (PLI) scheme to incentivize indigenous orphan drug manufacturing.